References
- Akabane T, Tabata K, Kadono K, Sakuda S, Terashita S, Teramura T. (2010). A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos 38:308–316.
- Boxenbaum H. (1984). Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 15:1071–1121.
- Boxenbaum H. (1986). Time concepts in physics, biology, and pharmacokinetics. J Pharm Sci 75:1053–1062.
- Boxenbaum H, Fertig JB. (1984). Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur J Drug Metab Pharmacokinet 9:177–183.
- Boxenbaum H, Ronfeld R. (1983). Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 245:R768–R775.
- Datamonitor. (2008). Biosimilars Series: Stakeholder Analysis - A Panoramic View of the Emerging Biosimilar Landscape. Report # DMHC2426.
- Datamonitor. (2009). Biosimilars series: Forecast analysis- Beyond the generics horizon. Report # DMHC2477.
- Dedrick R, Bischoff KB, Zaharko DS. (1970). Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 54:95–101.
- Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. (2011). Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 3:61–66.
- Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, Hurh E, Gibbs MA. (2011). Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 50:131–142.
- Espié P, Tytgat D, Sargentini-Maier ML, Poggesi I, Watelet JB. (2009). Physiologically based pharmacokinetics (PBPK). Drug Metab Rev 41:391–407.
- European Medicines Agency (EMA). (2006). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: non-clinical and clinical issues. European Medicines Agency, Committee for Medicinal Products for Human Use. EMEA/CHMP/BMWP/42832/2005. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf. Accessed on 5 March 2012.
- European Medicines Agency (EMA). Scientific Guidelines on Biosimilars. (2012). Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp&mid=WC0b01ac058002958c&jsenabled=true. Accessed on 15 March 2012.
- Gayon J. (2000). History of the concept of allometry. Am Zool 40:748–758.
- Huh Y, Smith DE, Feng MR. (2011). Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs. Xenobiotica 41:972–987.
- IDEC Pharmaceutical Corp. (1997) Rituximab, Biologic license Application: Preclinical and Clinical Pharmacology Review. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093352.htm. Accessed on 5 March 2012.
- Kleiber M. (1932). Body size and metabolism. Hilgardia 6:315–353.
- Ling J, Zhou H, Jiao Q, Davis HM. (2009). Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 49:1382–1402.
- Mahmood I. (2009a). Role of fixed coefficients and exponents in the prediction of human drug clearance: how accurate are the predictions from one or two species? J Pharm Sci 98:2472–2493.
- Mahmood I. (2009b). Pharmacokinetic allometric scaling of coagulation factors and tissue-type plasminogen activators. Haemophilia 15:1109–1117.
- Mahmood I. (2009c). Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci 98:3850–3861.
- Mahmood I, Balian JD. (1996). Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887–895.
- Mahmood I, Yuan R. (1999). A comparative study of allometric scaling with plasma concentrations predicted by species-invariant time methods. Biopharm Drug Dispos 20:137–144.
- Mascelli MA, Zhou H, Sweet R, Getsy J, Davis HM, Graham M, Abernethy D. (2007). Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol 47:553–565.
- Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. (1991). Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 8:1351–1359.
- Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58.
- Oitate M, Nakayama S, Ito T, Kurihara A, Okudaira N, Izumi T. (2012). Prediction of human plasma concentration-time profiles of monoclonal antibodies from monkey data by a species-invariant time method. Drug Metab Pharmacokinet 27:354–359.
- Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JW, Ku MS, Gibson CR, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Bjornsson T, Lave T, Poulin P. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance. J Pharm Sci. 100:4074–4089.
- Schellekens H. (2009). Biosimilar therapeutics-what do we need to consider? NDT Plus 2:i27–i36.
- Tang H, Hussain A, Leal M, Mayersohn M, Fluhler E. (2007). Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 35:1886–1893.
- Thygesen P, Macheras P, Van Peer A. (2009). Physiologically-based PK/PD modelling of therapeutic macromolecules. Pharm Res 26:2543–2550.
- U.S. Food and Drug Administration (US FDA). Bioavailability and BioequivalenceStudies for Orally Administered Drug Products - General Considerations. (2003). Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070124.pdf. Accessed on 9 September 2012.
- U.S. Food and Drug Administration (US FDA). Draft Guidances for Biosimilars. (2012). Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm. Accessed on 15 March 2012.
- Wajima T, Fukumura K, Yano Y, Oguma T. (2003). Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: volume of distribution at steady state. J Pharm Pharmacol 55:939–949.
- Wajima T, Yano Y, Fukumura K, Oguma T. (2004). Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci 93:1890–1900.
- Wang W, Prueksaritanont T. (2010). Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos 31:253–263.
- West GB, Brown JH. (2005). The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J Exp Biol 208:1575–1592.
- Woo S, Jusko WJ. (2007). Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos 35:1672–1678.